Enfusion (ENFN)
(Delayed Data from NYSE)
$8.81 USD
+0.11 (1.26%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $8.80 -0.01 (-0.11%) 7:36 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Enfusion, Inc. (ENFN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.71 | $12.00 | $8.00 | 11.61% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Enfusion, Inc. comes to $9.71. The forecasts range from a low of $8.00 to a high of $12.00. The average price target represents an increase of 11.61% from the last closing price of $8.70.
Analyst Price Targets (7 )
Broker Rating
Enfusion, Inc. currently has an average brokerage recommendation (ABR) of 2.88 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.88 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, three are Strong Buy, representing 37.5% of all recommendations. A month ago, Strong Buy represented 37.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ENFN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.88 | 2.88 | 2.88 | 2.88 | 2.88 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/10/2024 | Piper Sandler | Crispin Love | Hold | Hold |
3/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/13/2024 | William Blair | Dylan Becker | Strong Buy | Strong Buy |
2/28/2024 | Goldman Sachs | Gabriela Borges | Hold | Strong Sell |
11/7/2023 | UBS | Kevin D Mcveigh | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.88 |
ABR (Last week) | 2.88 |
# of Recs in ABR | 8 |
Average Target Price | $9.71 |
LT Growth Rate | 47.80% |
Industry | Internet - Software |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | 0.06 |